A Double-blind, Placebo- and Active-Controlled Evaluation of the Safety and Efficacy of Levomilnacipran ER in Adolescent Patients With Major Depressive Disorder
Latest Information Update: 01 Apr 2021
At a glance
- Drugs Levomilnacipran (Primary) ; Fluoxetine
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors Allergan; Forest Laboratories
- 27 Mar 2017 New trial record